Plague Research Today is a free monthly online journal that collates and summarizes the latest research about Plague, including details on bubonic plague, yersinia pestis, infection, types, treatment.

An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge.

Palin A, Chattopadhyay A, Park S, Delmas G, Suresh R, Senina S, Perlin DS, Rose JK

Department of Pathology, Yale University School of Medicine, 310 Cedar Street (LH 315), New Haven, CT 06510, USA.

We have developed recombinant vesicular stomatitis virus (VSV) vectors expressing the Yersinia pestis lcrV gene. These vectors, given intranasally to mice, induced high antibody titers to the LcrV protein and protected against intranasal (pulmonary) challenge with Y. pestis. High-level protection was dependent on using an optimized VSV vector that expressed high levels of the LcrV protein from an lcrV gene placed in the first position in the VSV genome, followed by a single boost. This VSV-based vaccine vector system has potential as a plague vaccine protecting against virulent strains lacking the F1 protein.

Published 12 December 2006 in Vaccine, 25(4): 741-50.
Full-text of this article is available online (may require subscription).

© 2005-2008 Plague Research Today. All Rights Reserved.